

Lead Product(s) : Bifidobacterium Infantis
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : B. Infantis is a Probiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Hematologic Neoplasms.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : Bifidobacterium Infantis
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

 Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.                    
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bifidobacterium Infantis
Therapeutic Area : Endocrinology
Study Phase : Undisclosed
Sponsor : Technical University of Munich | Kinderkrankenhaus auf der Bult | University Hospital Carl Gustav Carus | Skane University Hospital | Universitaire Ziekenhuizen KU Leuven | Medical University of Warsaw | Cambridge Biomedical Campus, Cambridge, UK | Royal
Deal Size : Inapplicable
Deal Type : Inapplicable
Supplementation With B. Infantis for Mitigation of Type 1 Diabetes Autoimmunity
Details : B. Infantis is a Probiotic drug candidate, which is currently being evaluated in clinical studies for the treatment of Diabetes Mellitus, Type 1.
Product Name : Undisclosed
Product Type : Probiotic
Upfront Cash : Inapplicable
February 24, 2021
Lead Product(s) : Bifidobacterium Infantis
Therapeutic Area : Endocrinology
Highest Development Status : Undisclosed
Sponsor : Technical University of Munich | Kinderkrankenhaus auf der Bult | University Hospital Carl Gustav Carus | Skane University Hospital | Universitaire Ziekenhuizen KU Leuven | Medical University of Warsaw | Cambridge Biomedical Campus, Cambridge, UK | Royal
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Bifidobacterium Infantis
Therapeutic Area : Gastroenterology
Study Phase : Phase IV
Sponsor : Genova Diagnostics
Deal Size : Inapplicable
Deal Type : Inapplicable
Irritable Bowel Syndrome Evaluation and Treatment in Primary Care
Details : Bifidobacterium Infantis is a drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Irritable Bowel Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 16, 2012
Lead Product(s) : Bifidobacterium Infantis
Therapeutic Area : Gastroenterology
Highest Development Status : Phase IV
Sponsor : Genova Diagnostics
Deal Size : Inapplicable
Deal Type : Inapplicable
